Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
BioNTech raises $270 million
by Ryan Cross
January 8, 2018
| A version of this story appeared in
Volume 96, Issue 2
BioNTech, a German company developing mRNA-based therapies, raised a healthy $270 million in its series A funding, led by Redmile Group. The firm’s mRNA therapies include vaccines for infectious diseases, cancer immunotherapy vaccines, and mRNA to make therapeutic proteins in the body. BioNTech has also added small-molecule and CART-cell cancer immunotherapy programs to its pipeline. BioNTech was founded in 2008 by scientists from Johannes Gutenberg University Mainz. Since then it has established pacts with firms such as Bayer Animal Health, Eli Lilly & Co., Genentech, Genmab, and Sanofi.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter